DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
DiaMedica Therapeutics Inc. (NASDAQ: DMAC Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Thomas Flaten - Lake Street Capital Kyle Bauser - Dougherty Operator Ladies and gentlemen, thank you for standing by and welcome to the DiaMedica Therapeutics Inc. Q4 2019 results earnings conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Rick Pauls, President and Chief Executive Officer. Thank you. Please go ahead, sir. Thank you Lisa. Good morning everyone. We hope you are all safe and well. We would like to welcome you to our year-end 2019 earnings and business update call. Yesterday, after the market closed, we issued a press release with a business update and summary of our fin
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- DiaMedica Therapeutics GAAP EPS of -$0.15 in-line [Seeking Alpha]Seeking Alpha
- DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial ResultsBusiness Wire
DMAC
Earnings
- 11/13/24 - Miss
DMAC
Sec Filings
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- DMAC's page on the SEC website